- Home
- ACRS vs RBKB Comparison
ACRS vs RBKB Comparison
Compare ACRS & RBKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- RBKB
- Stock Information
- Founded
- ACRS 2012
- RBKB 1860
- Country
- ACRS United States
- RBKB United States
- Employees
- ACRS N/A
- RBKB N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- RBKB Banks
- Sector
- ACRS Health Care
- RBKB Finance
- Exchange
- ACRS Nasdaq
- RBKB Nasdaq
- Market Cap
- ACRS 137.5M
- RBKB 111.3M
- IPO Year
- ACRS 2015
- RBKB 2019
- Fundamental
- Price
- ACRS $1.46
- RBKB $11.58
- Analyst Decision
- ACRS Strong Buy
- RBKB
- Analyst Count
- ACRS 8
- RBKB 0
- Target Price
- ACRS $9.71
- RBKB N/A
- AVG Volume (30 Days)
- ACRS 709.4K
- RBKB 8.5K
- Earning Date
- ACRS 05-08-2025
- RBKB 07-24-2025
- Dividend Yield
- ACRS N/A
- RBKB N/A
- EPS Growth
- ACRS N/A
- RBKB N/A
- EPS
- ACRS N/A
- RBKB N/A
- Revenue
- ACRS $17,777,000.00
- RBKB $28,027,000.00
- Revenue This Year
- ACRS N/A
- RBKB N/A
- Revenue Next Year
- ACRS $14.59
- RBKB N/A
- P/E Ratio
- ACRS N/A
- RBKB N/A
- Revenue Growth
- ACRS N/A
- RBKB N/A
- 52 Week Low
- ACRS $0.99
- RBKB $7.30
- 52 Week High
- ACRS $5.17
- RBKB $11.75
- Technical
- Relative Strength Index (RSI)
- ACRS 61.33
- RBKB 64.49
- Support Level
- ACRS $1.22
- RBKB $11.33
- Resistance Level
- ACRS $1.56
- RBKB $11.75
- Average True Range (ATR)
- ACRS 0.09
- RBKB 0.22
- MACD
- ACRS 0.03
- RBKB 0.03
- Stochastic Oscillator
- ACRS 75.00
- RBKB 83.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About RBKB Rhinebeck Bancorp Inc.
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one- to four-family residential real estate loans, and to purchase investment securities.